|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, December 13, 2016 ) Ovarian epithelial cancer is a disease in which malignant (cancer) cells form in the tissue covering the ovary. Early ovarian cancer may not cause any symptoms. When symptoms do appear, ovarian cancer is often advanced. Symptoms may include pain or swelling in the abdomen, pain in the pelvis and gastrointestinal problems, such as gas, bloating, or constipation. There are different types of treatment for patients with ovarian epithelial cancer such as surgery, radiation therapy, and chemotherapy.
Report Highlights
Publisher's Pharmaceutical and Healthcare latest pipeline guide Epithelial Ovarian Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Epithelial Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Epithelial Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Epithelial Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 11, 38, 23, 2, 11, 2 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 3 and 3 molecules, respectively.Epithelial Ovarian Cancer.
Epithelial Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/epithelial-ovarian-cancer-pipeline-review-h2-2016
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Epithelial Ovarian Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Epithelial Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Epithelial Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Epithelial Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Epithelial Ovarian Cancer (Oncology)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001492633/sample
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Epithelial Ovarian Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Epithelial Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Companies profiles
Adaptimmune Therapeutics Plc
Amgen Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Bayer AG
BioNumerik Pharmaceuticals Inc
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Company
Celldex Therapeutics Inc
Celon Pharma Sp z oo
Celsion Corp
CerRx Inc
Cerulean Pharma Inc
Clovis Oncology Inc
Dr. Reddy's Laboratories Ltd
EirGenix Inc.
Eisai Co Ltd
Eli Lilly and Company
Esperance Pharmaceuticals Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Gene Techno Science Co Ltd
Genentech Inc
Genor BioPharma Co Ltd
Glycotope GmbH
Ignyta Inc
ImmunoGen Inc
Incyte Corp
Innate Immunotherapeutics Ltd
Johnson & Johnson
Juno Therapeutics Inc
Mabion SA
MabVax Therapeutics Holdings Inc
Mateon Therapeutics Inc
MedImmune LLC
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001492633/discount
List of Figures
Number of Products under Development for Epithelial Ovarian Cancer, H2 2016 19
Number of Products under Development for Epithelial Ovarian Cancer - Comparative Analysis, H2 2016 20
Number of Products under Development by Companies, H2 2016 21
Number of Products under Investigation by Universities/Institutes, H2 2016 26
Comparative Analysis by Late Stage Development, H2 2016 27
Comparative Analysis by Clinical Stage Development, H2 2016 28
Comparative Analysis by Early Stage Products, H2 2016 29
Assessment by Monotherapy Products, H2 2016 105
Number of Products by Top 10 Targets, H2 2016 106
Number of Products by Stage and Top 10 Targets, H2 2016 106
Number of Products by Top 10 Mechanism of Actions, H2 2016 114
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 114
Number of Products by Top 10 Routes of Administration, H2 2016 122
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 122
Number of Products by Top 10 Molecule Types, H2 2016 124
Number of Products by Stage and Top 10 Molecule Types, H2 2016 124
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001492633/buy/2000
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
